Sam Brusco, Associate Editor06.03.24
Stryker announced a deal to acquire all issued and outstanding shares of Artelon, a privately-held company specializing in soft tissue fixation products for foot/ankle and sports medicine procedures.
Sandy Springs, Ga.-based Artelon produces differentiated synthetic technology designed to enhance biological and mechanical ligament and tendon reconstruction. Its products have been used with more than 60,000 implantations worldwide, according to the company.
The acquisition allows Stryker to have a more competitive position in the foot/ankle and sports medicine segment with a biomaterial technology that supports healing of soft tissues. It also highlights Stryker’s drive to offer differentiated solutions for reconstructing ligaments and tendons.
Stryker and Artelon will continue to operate as separate entities until the transaction closes. No financial details were disclosed.
“Artelon’s proven product portfolio and differentiated offerings will enhance our ability to innovate and serve our customers,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “The addition of Artelon’s products to our already robust foot and ankle and sports medicine product portfolios will fuel our goal of establishing comprehensive offerings for customers in these segments. We share a common dedication to integrity, quality, and advancing the knowledge of healthcare providers to achieve the best clinical outcomes and rebuild patients’ lives.”
Sandy Springs, Ga.-based Artelon produces differentiated synthetic technology designed to enhance biological and mechanical ligament and tendon reconstruction. Its products have been used with more than 60,000 implantations worldwide, according to the company.
The acquisition allows Stryker to have a more competitive position in the foot/ankle and sports medicine segment with a biomaterial technology that supports healing of soft tissues. It also highlights Stryker’s drive to offer differentiated solutions for reconstructing ligaments and tendons.
Stryker and Artelon will continue to operate as separate entities until the transaction closes. No financial details were disclosed.
“Artelon’s proven product portfolio and differentiated offerings will enhance our ability to innovate and serve our customers,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “The addition of Artelon’s products to our already robust foot and ankle and sports medicine product portfolios will fuel our goal of establishing comprehensive offerings for customers in these segments. We share a common dedication to integrity, quality, and advancing the knowledge of healthcare providers to achieve the best clinical outcomes and rebuild patients’ lives.”